跳转至内容
Merck
CN
  • Modeling type II collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells.

Modeling type II collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells.

Human molecular genetics (2014-09-05)
Minoru Okada, Shiro Ikegawa, Miho Morioka, Akihiro Yamashita, Atsushi Saito, Hideaki Sawai, Jun Murotsuki, Hirofumi Ohashi, Toshio Okamoto, Gen Nishimura, Kazunori Imaizumi, Noriyuki Tsumaki
摘要

Type II collagen is a major component of cartilage. Heterozygous mutations in the type II collagen gene (COL2A1) result in a group of skeletal dysplasias known as Type II collagenopathy (COL2pathy). The understanding of COL2pathy is limited by difficulties in obtaining live chondrocytes. In the present study, we converted COL2pathy patients' fibroblasts directly into induced chondrogenic (iChon) cells. The COL2pathy-iChon cells showed suppressed expression of COL2A1 and significant apoptosis. A distended endoplasmic reticulum (ER) was detected, thus suggesting the adaptation of gene expression and cell death caused by excess ER stress. Chondrogenic supplementation adversely affected the chondrogenesis due to forced elevation of COL2A1 expression, suggesting that the application of chondrogenic drugs would worsen the disease condition. The application of a chemical chaperone increased the secretion of type II collagen, and partially rescued COL2pathy-iChon cells from apoptosis, suggesting that molecular chaperons serve as therapeutic drug candidates. We next generated induced pluripotent stem cells from COL2pathy fibroblasts. Chondrogenically differentiated COL2pathy-iPS cells showed apoptosis and increased expression of ER stress-markers. Finally, we generated teratomas by transplanting COL2pathy iPS cells into immunodeficient mice. The cartilage in the teratomas showed accumulation of type II collagen within cells, a distended ER, and sparse matrix, recapitulating the patient's cartilage. These COL2pathy models will be useful for pathophysiological studies and drug screening.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
DL-二硫代苏糖醇 溶液, BioUltra, Molecular Biology, ~1 M in H2O
Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Supelco
DL-二硫代苏糖醇 溶液, 1 M in H2O
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
SAFC
L-谷氨酰胺
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Supelco
甲醇, analytical standard
Supelco
L -抗坏血酸, analytical standard
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
L -抗坏血酸, reagent grade